First identification of genotypes of Enterocytozoon bieneusi (Microsporidia) among symptomatic and asymptomatic children in Mozambique.

Enterocytozoon bieneusi is a human pathogen with a broad range of animal hosts. Initially, E. bieneusi was considered an emerging opportunistic pathogen in immunocompromised, mainly HIV-infected patients, but it has been increasingly reported in apparently healthy individuals globally. As in other African countries, the molecular epidemiology of E. bieneusi in Mozambique remains completely unknown. Therefore, we undertook a study to investigate the occurrence and genetic diversity of E. bieneusi infections in children with gastrointestinal symptoms as well as in asymptomatic children in Mozambique. Individual stool specimens were collected from 1,247 children aged between 0 and 14 years-old living in urban and rural settings in Zambézia (n = 1,097) and Maputo (n = 150) provinces between 2016 and 2019. Samples were analysed for E. bieneusi by nested-PCR targeting the internal transcribed spacer (ITS) region of the rRNA gene. All positive amplicons were confirmed and genotyped. Penalised logistic regression (Firth) was used to evaluate risk associations. The overall prevalence of E. bieneusi in this children population was 0.7% (9/1,247). A 10-fold higher prevalence was found in Maputo (4.0%; 6/150) than in Zambézia (0.3%; 3/1,097). All E. bieneusi-positive samples were from children older than 1-year of age, and most (8/9) from asymptomatic children. Nucleotide sequence analysis of the ITS region revealed the presence of four genotypes, three previously reported (Peru11, n = 1; Type IV, n = 2, and S2, n = 2) and a novel genotype (named HhMzEb1, n = 4). Novel genotype HhMzEb1 was identified in both asymptomatic (75%, 3/4) and symptomatic (25%, 1/4) children from a rural area in Maputo province in southern Mozambique. Genotypes HhMzEb1, Peru11, S2, and Type IV belonged to the Group 1 that includes genotypes with low host specificity and the potential for zoonotic and cross-species transmission. Being infected by enteric protozoan parasites and no handwashing were identified as risk associations for E. bieneusi infection. This study reports the first investigation of E. bieneusi genotypes in Mozambique with the identification of three previously reported genotypes in humans as well as a novel genotype (HhMzEb1). Findings highlight the need to conduct additional research to elucidate the epidemiology of E. bieneusi in the country, especially in rural areas where poor hygiene conditions still prevail. Special attention should be paid to the identification of suitable animal and environmental reservoirs of this parasite and to the characterization of transmission pathways.

Introduction

Microsporidia comprises 200 genera and nearly 1,500 species of spore-forming parasites ubiquitously found in the environment and able to colonize/infect a wide variety of invertebrate and vertebrate hosts [1,2]. Among the 17 Microsporidia species infecting humans Enterocytozoon bieneusi is the most frequently reported, causing gastrointestinal infections globally [3]. Infections with E. bieneusi in immunocompromised individuals (e.g. patients with AIDS, cancer, organ transplant recipients, and the elderly) are usually associated with chronic diarrhoea, wasting syndrome, and weight loss. Infections in immunocompetent subjects are often asymptomatic or result in self-limited diarrhoea and malabsorption [4,5]. Extraintestinal disorders and pathologies have also been reported, mainly in lung [6]. In addition, E. bieneusi infection in early childhood has been recently linked to impaired growth in children in low-resource settings including African countries such as Malawi, South Africa, or Tanzania [7,8]. Enterocytozoon bieneusi has a high genetic diversity and is capable of colonizing/infecting a broad spectrum of mammal and avian species. There are marked differences in host specificities and zoonotic potential among those genotypes [9-11]. Infections are acquired through ingestion of food and water contaminated with E. bieneusi spores, or through direct contact with faeces of infected persons and animals or with contaminated soils [2,12,13].

The highly polymorphic ribosomal internal transcribed spacer (ITS) of the ribosomal rRNA (rRNA) gene is the most widely used marker for assessing the genetic diversity within E. bieneusi [11]. Based on ITS nucleotide sequences nearly 500 genotypes have been validated according to current nomenclature standards that are distributed into 11 distinct phylogenetic groups [10,14]. Groups 1 and 2 comprise genotypes able to infect a broad range of mammalian species including humans and are, therefore, considered potentially zoonotic. On the other hand, groups 3‒11 have strong host specificities and are considered to pose little or null zoonotic risk [11].

The Global Enteric Multicenter Study (GEMS) has provided important information on the aetiology and population-based burden of paediatric diarrheal diseases in sub-Saharan Africa and South Asia. GEMS included in their study enteric protozoan parasites Giardia duodenalis, Cryptosporidium spp., and Entamoeba histolytica, but not the microsporidia E. bieneusi [15]. However, in recent years there has been a steady increase in the studies aiming to improve our understanding of the epidemiology of E. bieneusi in Africa since this parasite is frequently reported in immunocompromised individuals in African countries (Table 1 and S1 Fig). Importantly, early microscopy-based studies documented E. bieneusi prevalences as high as 40‒67% in apparently healthy people in Cameroon [16] and Nigeria [17]. These findings indicate that asymptomatic, chronic E. bieneusi infections could be more frequent than anticipated. Despite the undoubted progress achieved over the past years, the actual epidemiological situation of E. bieneusi in most African countries, including Mozambique, remains largely unknown. To fill this gap, the present study aims to investigate the occurrence and genetic diversity of E. bieneusi in symptomatic and asymptomatic paediatric populations in two of the most populous provinces of Central (Zambézia) and Southern (Maputo) Mozambique.

Table 1

Enterocytozoon bieneusi infections reported in humans in African countries including country of origin, type of surveyed population, symptomatology, diagnostic method, and reported prevalence and genotypes.

Diagnosis was conducted in stool samples except otherwise indicated.

Country	Surveyed population	Clinical manifestations	Diagnostic method	Prevalence (%)	Genotype(s)	Reference
Cameroon	HIV+/TB+; HIV‒/TB+; Immunocompetent	Diarrhoea	LM, IFAT	35.7 (10/28); 24.0 (6/25); 67.5 (85/126)	ND	[16]
	HIV‒; HIV+	NS	IFAT, PCR	2.9 (22/758); 0.5 (4/758)	A (8), B (3), CAF4 (5), D (3), Type IVc (1)	[36]
	HIV+ (adults)	Diarrhoea, asymptomatic	LM, PCR-RFLP	6.5 (3/46); 4.6 (5/108)	Type IV (4)	[39]
	HIV‒	None	PCR	2.6 (5/196)	CAF1d (1), Type IV (4)	[51]
Chad	HIV+a	Diarrhoea	LM, IFAT, PCR	100 (1/1)	ND	[52]
Democratic Republic of the Congo	HIV+ (> 15 yrs.)	Diarrhoea	PCR	7.8 (19/242)	D (1), CAF1d (1), KIN-2 (1), KIN-3 (1), NIA1 (1)	[53]
	AIDS patients (> 15 yrs.)	Diarrhoea	IFAT, PCR	5.1 (9/175)	NIA1 (2)	[54]
	AIDS patients	Diarrhoea, other	LM, IFAT,	2.0 (1/50)	ND	[55]
Democratic Republic of São Tome and Principe	Rural children; Urban inpatient children	Diarrhoea, other	PCR	5.2 (7/134); 8.9 (19/214)	CAF1d (4), KIN-3 (1), Type IV (14), A (2), D (5)	[30]
Ethiopia	HIV+, HIV‒ (adults)	Diarrhoea	U2B, PCR	14.3 (15/105)	ND	[56]
	HIV+, HIV‒ (adults)	Diarrhoea, other	LM, PCR	12.3 (30/243)	ND	[57]
Gabon	HIV+ (> 16 yrs.)	Diarrhoea	IFAT, PCR	3.0 (25/822)	A (1), CAF1 (3), CAF2 (1), CAF3 (1), CAF4 (4), D (1), Type IVc (4)	[36]
Kenya	HIV+ (adults)	Diarrhoea	U2B	3.0 (1/36)	ND	[58]
Madagascar	Inpatients (adults)	Diarrhoea, asymptomatic	PCR	1.5 (1/67); 2.5 (5/198)	ND	[59]
Malawi	HIV+, HIV‒	NS	PCR	100 (37/37)b	D (4), Type IVc (9), Peru8 (1), S1 (1), S2 (11), S3 (2), S4 (1), S5 (4), S6 (2), UG2145 (1),	[35]
	HIV+ (< 18 yrs.)	Diarrhoea, other	qPCR	37.0 (13/35)	ND	[7]
Mali	HIV+ (adults); HIV‒ (adults)	Diarrhoea	TEM, LM	32.0 (28/88); 27.0 (3/11)	ND	[60]
	HIV+ Immunocompetent children	Diarrhoea	U2B, IFAT, PCR	14.8 (9/61); 0.0 (0/71)	ND	[61]
Mozambique	Children and adults	Asymptomatic	PCR	9.0 (27/301)	ND	[27]
	Children	Diarrhoea, asymptomatic	PCR	0.3 (1/331); 0.9 (8/916)	HhMzEb1 (4), Peru11 (1), Type IV (2), S2 (2)	This study
Niger	HIV+ (Adults); HIV‒ (children)	Diarrhoea, other	TEM, LM	7.0 (4/60); 0.8 (8/990)	ND	[62]
	HIV+ (mostly adults)	NS	LM, qPCR	10.5 (24/228)	A (10), CAF1 (2), D (2), E (1), HAN1 (1) Type IVc (1), NIA1 (3)	[41]
Nigeria	Rural/urban dwellers	NS	LM	39.6 (80/204)	ND	[17]
	HIV‒ (children)	Diarrhoea, asymptomatic	PCR	9.3 (4/43)	D (2), Type IVc (1), novel K-like (1)	[31]
	HIV+, HIV‒	Diarrhoea, other	PCR	6.4 (10/157)	A/Type IV (1), D (3), D/WL7 (1), Type IV (1), WL7 (3), WL7/Type IV (1)	[42]
	HIV+ (adults)	Diarrhoea, other	PCR	26.5 (26/98); 4.3 (52/365)	A (22), CAF2 (2), D (31), D/Type IV (1), EbpA (1), Type IV (14), Nig1(1), Nig2 (1), Nig3 (1), Nig4 (1), Nig5 (1), Peru8 (1)	[43]
	HIV+	Diarrhoea	PCR	7.7 (10/132)	D (1), Nig2 (2), Peru8 (1), Nig4-like (1), Type IV (5)	[63]
	HIV+ (adults on HAART)	Diarrhoea, asymptomatic	PCR	11.1 (12/108); 3.4 (6/177)	Mixed genotypes (3), Nig4 (2), Nig6 (10), Nig7 (2), Type IV (1)	[64]
	HIV+	Diarrhoea, asymptomatic	LM, IFAT, PCR	2.6 (5/193)	B (1), P-like, Peru3, PtEb IV, PtEb V, Type IV, UG2145 (2)	[65]
	HIV+ (adults)	Diarrhoea	PCR	5.5 (5/90)	Type IV (4), unknown mixed infection (1)	[66]
South Africa	HIV+ (inpatients); HIV‒ (children)	Diarrhoea	LM, PCR-RFLP, qPCR	12.9 (33/255); 4.5 (3/67)	ND	[32]
Tanzania	HIV+ (adults); HIV+, HIV‒(children)	Diarrhoea, other; Chronic diarrhoea; Acute diarrhoea; Asymptomatic	LM, TEM	3.5 (3/86); 3.4 (2/59); 0.0 (0/55); 20.0 (4/20)	ND	[34]
Tunisia	Immunocompromised patients	Diarrhoea	LM, PCR	3.5 (3/86)	ND	[67]
	HIV+ (newborn)	Asymptomatic	LM, PCR	100 (1/1)	ND	[68]
	HIV+ (adults); HIV‒ (adults)	Diarrhoea, other	LM, PCR	20.0 (7/35); 5.3 (3/56)	ND	[69]
	HIV+ (adults)	Diarrhoea	LM, PCR	2.5 (3/119); 5.9 (7/119)	ND	[70]
	HIV+ (mostly adults)	Diarrhoea	LM, PCR	100% (7/7)	B (2), D (4), Peru8 (1)	[71]
	HIV+ (adults)	Diarrhoea, asymptomatic	LM, PCR	19.4 (6/31); 2.8 (2/71)	ND	[72]
Uganda and Zambia	HIV+b	Diarrhoea, other	LM, TEM	6.5 (5/77)	ND	[73]
	Children (< 5 yrs)	Diarrhoea, asymptomatic	LM, PCR	17.4 (310/1779); 16.8 (112/667)	Type IVc (6), UG2145 (1)	[40]
	HIV+ (children); HIV‒ (children)	Diarrhoea, other	PCR	76.9 (70/91); 6.6 (10/152)	ND	[33]
Zambia	Rural children	Asymptomatic	U2B, TEM	0.6 (1/176)	ND	[74]
Zimbabwe	HIV+ (adults)	Diarrhoea	LM	10.0 (13/129)	ND	[75]
	HIV+ (adults)	Diarrhoea	LM, PCR	46.0 (34/74)	ND	[76]
	HIV+ (adults)	Diarrhoea	LM, PCR	18.0 (10/55); 51.0 (28/55)	ND	[77]
	HIV‒	Diarrhoea, other	LM, PCR	33.0 (2/6)	ND	[78]

HAART, Highly active antiretroviral therapy; HIV, Human immunodeficiency virus; IFAT, immunofluorescence antibody test; LM, light microscopy; ND, not determined; NS, not specified; PCR, polymerase chain reaction; qPCR, real-time PCR; RFLP, restriction fragment length polymorphism; TB, Tuberculosis; TEM, Transmission electron microscopy; U2B, Uvitex 2B fluorescent dye.

a Patient from Chad diagnosed in France.

b Diagnosed in an intestinal biopsy.

c Reported as genotype K.

d Reported as genotype KIN-1.

Methods

Ethics statement

Written informed consent was obtained from legal guardians of children voluntarily participating in this survey. All procedures involved in the study were approved by the Ethics Committee of the Health Institute Carlos III under reference number CEI PI 17_2017-v3, and the National Bioethics Committee for Health (CNBS–Comité Nacional de Bioética para Saúde) of Mozambique under reference number 52/CNBS/2017 (participants in Zambézia). Similarly, approval by the Centro de Investigação em Saúde de Manhiça’s Institutional Bioethics Committee for Health—CIBS (Ref. CIBS-CISM/075/2015), with final approval by CNBS (Ref. 209/CNBS/15), were obtained for participants in Maputo.

Study design

This study is part of an ongoing research collaborative effort involving the Spanish National Centre for Microbiology (SNCM) in Spain, the Centro de Investigação em Saúde de Manhiça (CISM)/Fundação Manhiça (FM) in Mozambique, and the United States Department of Agriculture to assess the molecular epidemiology of the most frequent enteric protist parasites infecting humans in Mozambique. Two independent studies involving different sampling designs were conducted in Zambézia and Maputo provinces.

Collection of stool samples in Zambézia province

Zambézia (population: 5.1 million; total area: 103,478 km2) is the second most-populous province of Mozambique, located in the central coastal region of the country. A prospective cross-sectional molecular epidemiological study was carried out between October 2017 and February 2019. All enrolled children were between 3 and 14 years old. A first set of samples were obtained from school children attending 18 public schools with each 35‒2,111 (mean: 651) children in 10 of the 22 districts of Zambézia. Voluntary participants were provided with sampling kits (sterile polystyrene plastic flask with spatula and a unique identification number) to obtain individual stool samples. In addition, a second set of samples from children presenting with gastrointestinal complaints (abdominal pain, anal pruritus, bloating, constipation, diarrhoea, flatulence, loss of appetite, nausea, vomiting) seeking medical attention in health care centres (n = 6) and hospital settings (n = 1) from six districts of the province were collected.

For both sets, an aliquot of each faecal sample was transferred to a TOTAL-FIX stool collection device (Durviz, Valencia, Spain) and shipped to SNCM in Majadahonda (Spain) for downstream molecular analyses.

Collection of stool samples in Maputo province

The study in the Maputo province was conducted in the Manhiça district (population: 0.2 million; total area: 2,373 km2) that is located approximately 80 km north of the capital city Maputo in Southern Mozambique. The Manhiça district has been under a Health and Demographic Surveillance System (HDSS) from CISM since 1996, allowing the link between demographic and clinical data of the population [18].

Stool samples were collected from children under 5 years of age under an ongoing surveillance of diarrheal diseases conducted by the CISM since September 2015 in the Manhiça District Hospital (MDH) and other health peripheral facilities [18,19]. Children under 5 years of age presenting to the peripheral health facilities with moderate-to-severe and less-severe diarrhoea were recruited. Definition of diarrhoeal cases and inclusion criteria to participate in the research study were as previously described [20]. In addition, starting from December 2016, 1 to 3 community controls (asymptomatic children free of diarrhoea episode > 14 days) matched to the index case by age, sex and neighbourhood were identified (using the HDSS databases) and enrolled within 14 days after said index case was enrolled. Stools were collected for both cases and controls and sent to the laboratory for processing. Additionally, stools from children presenting to the sentinel health facility complaining with less-severe diarrhoea and those children presenting to the Xinavane Rural Hospital (XRH), were enrolled starting in April 2017 up to December 2018. Stool samples were collected in sterile flasks, transported to the laboratory, and stored at ‒80°C without any preservatives for further testing of enteric pathogens as previously described [21].

Data collection

Epidemiological and clinical information was collected in a standardized questionnaire provided as part of the sampling kits and labelled with the same identification number. The questionnaire was completed by researchers interviewing participating children and their caretakers at the time of sampling. The questionnaire included basic demographic characteristics (age, sex, place of living), and potential risk factors including contact with livestock or companion animals, type of drinking water, and information regarding the defecation place. There were some differences between Manhiça and Zambézia questionnaires.

DNA extraction and purification

In stool samples from Zambézia, DNA was isolated from 200 mg of faecal material using the QIAamp Fast DNA stool mini Kit and the QIAcube robot (Qiagen, Hilden, Germany) following the manufacturer's instructions except that treatment of the samples with the lysis buffer was carried out for 10 minutes at 95°C. Purified DNA samples (200 μL) were stored at -20 ºC for downstream molecular analysis. In Manhiça, DNA was manually extracted and purified using the QIAamp DNA Stool Mini Kit from 200 mg of faecal material following the manufacturer's instructions, with the same modification for the lysing step. Purified DNA samples (200 μL) were shipped to the SNCM for molecular testing.

Molecular detection of Enterocytozoon bieneusi

To detect E. bieneusi, a nested PCR was conducted to amplify a 390-bp fragment including the entire ITS as well as portions of the flanking large and small subunit of the rRNA gene [22]. Primary and secondary reactions (50 μL) were carried out using the outer primer set EBITS3 (5´‒GGTCATAGGGATGAAGAG‒3´) and EBITS4 (5´‒TTCGAGTTCTTTCGCGCTC‒3´), and the inner primer set EBITS1 (5´‒GCTCTGAATATCTATGGCT‒3´) and EBITS2.4 (5´‒ATCGCCGACGGATCCAAGTG‒3´), respectively. Reaction mixtures consisted of 1 μL of template DNA, 200 nM of each primer, 2.5 units of MyTAQ DNA polymerase (Bioline GmbH, Luckenwalde, Germany), and 5 μL of MyTAQ Reaction Buffer containing 5 mM dNTPs and 15 mM MgCl2. Cycling conditions for the primary PCR were as follows: after denaturation at 94°C for 3 min, samples were subjected to 35 cycles of amplification (denaturation at 94°C for 30 s, annealing at 57°C for 30 s, and elongation at 72°C for 40 s), followed by a final extension at 72°C for 10 min. Conditions for the secondary PCR were identical to the primary PCR except only 30 cycles were carried out with an annealing temperature of 55°C. Negative (no DNA template) and positive (E. bieneusi PCR-positive samples, genotypes Ebcar2 and EbpA) controls were included in all PCR runs. PCR products were resolved on 2% D5 agarose gels (Conda, Madrid, Spain) stained with Pronasafe (Conda).

Sequence analysis

All amplicons of the expected size were directly sequenced in both directions using the internal primer set in 10 μL reaction mixes using Big Dye chemistries and an ABI 3730xl sequencer analyser (Applied Biosystems, Foster City, CA). Sequencing data were viewed using Chromas Lite version 2.1 software (https://technelysium.com.au/wp/chromas/) to generate consensus sequences. The Blast tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to compare those sequences with reference sequences deposited at the National Center for Biotechnology Information (NCBI). Enterocytozoon bieneusi genotypes were determined using the established nomenclature system based on ITS nucleotide sequence [14]. Sequences obtained in the present study were deposited in the GenBank database under accession numbers MN845065 to MN845068.

Phylogenetic analysis

Nucleotide sequences obtained in this study and E. bieneusi nucleotide sequences for all genotypes previously identified in human and animals in Africa as well as appropriate reference sequences to include all E. bieneusi groups retrieved from GenBank were aligned with the Clustal W algorithm using MEGA X [23]. Phylogenetic inference was carried out by the Neighbor-Joining (NJ) method as previously described [24], genetic distance was calculated with the Kimura parameter-2 model using MEGA X [23].

Statistical analysis

We analysed the data using EpiData 4.2.0 (EpiData Association, Odense, Denmark) and Stata software, versions 15 (STATA Corp., College Station, Texas, US). We calculated odds ratios (OR) for associations; a probability (P) value < 0.05 was considered evidence of statistical significance. We examined for possible confounders (change of > 20% in OR) and interactions. As both populations included selection by symptomatic and asymptomatic populations, we included “a priori” the symptomatic variable in the multivariable model. As the event was rare, and some factors (e.g. G. duodenalis) were found in all cases, we used a penalised regression (Firth regression) selecting risk factors with a P-value ≤ 0.2 from the univariable analysis, using Akaike's information criterion (AIC) and Bayesian information criterion (BIC) to determine selection and evaluate the final model [25].

Results

A total of 1,247 children aged between 0 and 14 years-old were recruited to participate in this study in the Manhiça District in Maputo (n = 150) and Zambézia province (n = 1,097) in Mozambique. The main socio-demographic and epidemiological features of these paediatric populations are summarized in Table 2.

Table 2

Main socio-demographic and epidemiological features, expressed as frequencies, of the Mozambican children populations (n = 1,247) investigated in the present study.

	Zambézia			Manhiça district–Maputo
	Asymptomatic (n = 807)	Symptomatic (n = 290)	Total (n = 1,097)	Asymptomatic (n = 109)	Symptomatic (n = 41)	Total (n = 150)
Gender
Male	49.7	50.3	49.9	54.1	48.8	52.7
Female	50.3	49.7	50.1	45.9	51.2	47.3
Age group (years)
0‒5	13.4	33.8	18.8	100	100	100
6‒10	64.3	49.3	60.3	NA	NA	NA
11‒14	22.3	16.9	20.9	NA	NA	NA
Area
Rural	86.5	43.8	75.2	100	100	100
Urban	13.5	56.2	24.8	NA	NA	NA
Contact with livestock
Yes	4.6	14.1	7.1	59b	46.3c	55.3b
No	95.4	85.9	92.9	41b	53.7c	44.7b
Contact with dogs/cats
Yes	18.8	26.6	20.9	30b	19.5c	26.9b
No	81.2	73.4	79.1	70b	80.5c	73.1b
Main drinking water source
River/springs	4.3a	4.1	4.3a	2b	2.4	3.6b
Tap	23.2a	54.1	31.4a	91b	80.5	86.5b
Well	72.0a	41.7	64.0a	7b	17.1	9.9b
Defecation place
Latrine	88.0	76.9	85.1	100 c	100 d	100 e
Outside	12.0	23.1	14.9	0.0 c	0.0 d	0.0 e

NA: not applicable.

a Information for four children was not available.

b Information for nine children was not available.

c Information for one child was not available.

d Information for five children was not available.

e Information for six children was not available.

In Zambézia, 807 asymptomatic schoolchildren and 290 children presenting with gastrointestinal complaints seeking for medical care were investigated in 10 and six districts of the province, respectively (Table 2 and S1 and S2 Tables). The overall male/female ratio was 1.0, and children in the age group 6 to 10 years-old represented 60% of the surveyed individuals. Three out of four children investigated lived in rural areas.

In the rural Manhiça district, 109 asymptomatic children and 41 children presenting with gastrointestinal complaints (11 with moderate-to-severe diarrhoea and 30 with less severe diarrhoea) and seeking for medical care were investigated (Table 2 and S3 and S4 Tables). In this subpopulation, the male/female ratio was 1.1, and children in the age group 12–23 months-old represented 40.7% of the surveyed individuals. Most children (62.7%) were from the area covered by the MDH. All these children lived in rural areas.

Overall, E. bieneusi was detected by nested-PCR and confirmed by sequencing in 0.7% (9/1,247, 95% CI: 0.4–1.4) of the investigated children population. The prevalence was more than 10-fold higher in the Manhiça district in Maputo (4.0%, 6/150, 95% CI: 1.8–8.6) compared to all the districts in Zambézia combined (0.3%, 3/1,097, 95%CI: 0.1–0.8). The prevalence for those without symptoms was 0.9% (8/916, 95% CI: 0.4–1.7) and for those with symptoms 0.3% (1/331, 95% CI: 0.04–2.1), and those with diarrhoea 0.4% (1/251, 95% CI: 0.06–2.8). Nucleotide sequences of the ITS revealed the presence of four distinct E. bieneusi genotypes, three previously reported in humans (Type IV, S2, and Peru11) and a novel genotype (named HhMzEb1). No mixed infections were observed. Novel genotype HhMzEb1 differed from genotype D (AF101200) by one nucleotide. Genotype S2 nucleotide sequence obtained in this study showed a SNP at the large subunit region when compared with reference sequence (GenBank accession number FJ439678).

The main socio-demographic, epidemiological, and genotypes identified in each of the E. bieneusi infections identified in the present study are shown in Table 3. In the Zambézia province, E. bieneusi was found in 3 asymptomatic children. Two of them lived in a rural area, attended the same school, but were infected by different genotypes (Peru11 and S2) of the parasite. Both children were co-infected with G. duodenalis, Blastocystis sp., and Strongyloides spp. The third child was infected by the Type IV genotype of E. bieneusi and was co-infected with G. duodenalis. None of the symptomatic children investigated in this province tested positive to E. bieneusi.

Table 3

Main socio-demographic features, risk factors, and genotyping data of Mozambican children positive to Enterocytozoon bieneusi (n = 9) in the present study.

Province	District	Sample ID	Area	Gender	Age	Contact with livestock and/or poultry	Contact with companion animals	Main source of drinking water	Defecation place	Genotype	GenBank accession number
Zambézia	Gurúe	18	Urban	Male	132 months-old	No	Cat, dog	Public tap	Latrine	Type IV	MN845065
	Mocuba	207	Rural	Male	60 months-old	No	No	Well	Outside	Peru11	MN845067
	Mocuba	210	Rural	Female	60 months-old	No	No	Well	Outside	S2	MN845066
Maputo	Manhiça–MDH	1728661.9a, c, d	Rural	Male	16 months-old	Poultry	No	Public tap	Latrine	HhMzEb1b	MN845068
	Manhiça–MDH	1725028.3	Rural	Male	28 months-old	ND	ND	ND	Latrine	HhMzEb1b	Identical to MN845068
	Manhiça–XRH	1754917.2e	Rural	Male	16 months-old	ND	ND	ND	Latrine	HhMzEb1b	Identical to MN845068
	Manhiça–XRH	1725031.3d, e	Rural	Male	12 months-old	No	No	Public tap	Latrine	Type IV	Identical to MN845065
	Manhiça–XRH	1754898.4	Rural	Male	12 months-old	Goat, poultry	No	Unprotected well	Latrine	S2	Identical to MN845066
	Manhiça–MDH	1754369.9f	Rural	Male	15 months-old	No	No	ND	Latrine	HhMzEb1b	Identical to MN845068

ND: no data available; MDH: Manhiça District Hospital; XRH: Xinavane Rural Hospital.

a Symptomatic child presenting with moderate-to-severe diarrhoea.

b Novel genotype.

c Co-infected with Cryptosporidium meleagridis and HIV positive.

d Deceased.

e Co-infected with Rotavirus.

f Co-infected with Cryptosporidium parvum.

In Maputo province, E. bieneusi was found in six male children, one presenting with moderate-to-severe diarrhoea and 5 asymptomatic. Five out of the six cases were younger than 2 years old. The S2 and Type IV genotypes were found in a single boy each, one of them co-infected with Rotavirus. Among the 4 boys infected with the novel genotype, HhMzEb1, one was HIV positive, presented with moderate-to-severe diarrhoea, and was co-infected with Cryptosporidium meleagridis. Another boy with this genotype was co-infected with C. parvum, and a third one was co-infected with Rotavirus. All six E. bieneusi-positive samples were co-infected with G. duodenalis.

Univariable analysis (Table 4) of the combined data showed that significant risk associations included infections with G. duodenalis or Cryptosporidium spp. and age, but handwashing was protective. In the Zambézia dataset alone, G. duodenalis was a significant association. In addition, travel, Blastocystis sp., and absence of a latrine were associated with presence of E. bieneusi (P value < 0.5), but confidence intervals crossed 1, with only 3 positive cases. In the Maputo dataset there were no significant associations. In the final multivariable model using the combined dataset, after adjusting for symptoms, the risk associations for E. bieneusi were infection with G. duodenalis [OR: 19.11, P = 0.43, 95% CI (1.10–332.94)]; infection with Cryptosporidium spp. [OR 5.75, P = 0.49 95% CI (1.01–32.89)] and handwashing [OR 0.31 P = 0.128 95%CI (0.67–1.41)]. Although handwashing was not significant, it was retained in the final model as it confounded the relationship with Cryptosporidium spp. Age was not a factor after adjustment for other variables.

Table 4

Descriptive and univariable analysis of the variables of interest potentially associated with an increased exposure risk to Enterocytozoon bieneusi in the present study.

Variable	Cases of E. bieneusi with variable	%	Non cases with variable	%	Odds ratio	95% CI	P value
Cryptosporidium spp.	2	22	35	3	9.82	0.96–53.84	0.001
Giardia duodenalis	9	100	556	45	15.27	2.87–.	0.001
Age	Continuous				0.66	0.51–0.85	0.001
Handwashing (yes)	6	67	1152	93	0.14	0.03–0.86	0.001
Male Sex	7	78	622	50	3.47	0.66–34.29	0.1
Has livestock	2	22	150	12	3.61	0.32–25.37	0.115
Water source (not tap water)	3	33	885	71	0.39	0.05–2.94	0.236
Symptomatic	1	11	330	27	0.34	0.01–2.58	0.293
Blastocystis sp.	2	22	156	13	1.98	0.20–10.51	0.387
No latrine	2	22	162	13	1.89	0.19–10.01	0.423
Rural	8	89	967	78	2.24	0.30–99.83	0.435
Has pets (dog/cats)	1	11	267	22	0.72	0.02–6.50	0.766
Stronglyloides stercoralis	2	22	253	20	1.11	0.11–5.88	0.895
Entamoeba dispar	1	11	122	10	1.14	0.03–8.65	0.9

95% CI: 95% Confidence Interval.

Phylogenetic analysis revealed that the novel genotype HhMzEB1 clustered within Group 1 when its relationship with other genotypes of human and animal origin previously reported in Africa was evaluated (Fig 1).

Fig 1

Phylogenetic relationships among Enterocytozoon bieneusi genotypes identified in this study.

All genotypes identified in humans and animals in Africa, and genotypes to cover all groups of E. bieneusi were included for comparative purposes. Analyses were inferred by a Neighbor-Joining method of the entire ITS of rRNA gene based on genetic distances calculated by the Kimura two-parameter model (MEGA X software). All nucleotide sequences include host information with the GenBank accession number in parenthesis. Nucleotide sequences determined in this study are identified with black circles before the genotype name. White circles indicate genotypes identified in Africa.

Discussion

Little information is currently available on the occurrence and distribution of enteric parasites in Mozambique [26-28], although the GEMS project has significantly improved our understanding of the epidemiology of diarrhoea-associated with parasites G. duodenalis, Cryptosporidium spp., and E. histolytica [15, 29]. However, there is almost no information regarding Microsporidia, and only one study that aimed to investigate the prevalence of intestinal parasite infections in an informal settlement in Beira, Mozambique has reported E. bieneusi [27]. They detected E. bieneusi by real-time PCR in 9.3% (28/301) of the individuals tested and no genotyping was provided. Therefore, this is to our knowledge the first molecular epidemiological study describing occurrence and genetic diversity of E. bieneusi in Mozambique. The overall prevalence of E. bieneusi infection in the paediatric (0‒14 years of age) populations from Mozambique tested in this study was 0.7% (9/1,247). Infections were more commonly identified in asymptomatic children in rural settings.

The E. bieneusi infection rates found in our paediatric populations in Zambézia (0.3%) and Maputo (4%) were lower than the prevalence reported in Beira in Sofala province (9%) [27], indicating potential differences in the geographical distribution of the parasite in Mozambique. The disparity could also be associated with differences in socioeconomic characteristics of the studied population as the study in Beira was conducted in an informal settlement in an area that is frequently flooded and not connected to a sewage system after a local hospital noticed high number of diarrhoea cases in this settlement. Prevalence in Mozambique (0.7%) is lower to those previously documented in immunocompetent children populations (range: 4‒9%) in other African countries including the Democratic Republic of São Tomé and Principe [30], Nigeria [31], South Africa [32], and Uganda [33], and much lower than those found in similar paediatric populations (range: 20‒67%) in Cameroon [16], Nigeria [17], and Tanzania [34] (see Table 1). However, prevalence is influenced by the age group selected in the study and the presence of symptoms, so comparisons among studies must keep those differences in mind.

It is noteworthy to indicate that all E. bieneusi-positive children were also co-infected by other pathogens including two children in Manhiça that were HIV-positive. Indeed, one to three additional enteric parasites (G. duodenalis, Cryptosporidium spp., Blastocystis sp., and Strongyloides spp.) were found and the strongest risk associations were with G. duodenalis and Cryptosporidium spp. These data clearly depict a highly endemic scenario where polyparasitism is common as previously reported in the city of Beira [27].

Our study is limited by the small number of positive samples, thus the wide confidence intervals for our results. Furthermore, detailed information on handwashing (use of soap or not) and latrine use (toilet or outside latrine) were unavailable in the Zambézia dataset, and missing values for water source and animal livestock in the Maputo dataset implied limited exploration of these associations, especially given the low numbers of cases.

Nucleotide sequence analysis on the ITS region of the nine positive cases revealed the presence of four genotypes, three previously reported (Peru11, Type IV, and S2) and a novel genotype (named HhMzEb1). This constitutes the first report of these genotypes in Mozambique. Genotypes Type IV and S2 were both identified in Zambézia and Maputo, while Peru11 was only identified in Zambézia and novel genotype HhMzEb1 only in Maputo. All genotypes identified in the present study, including novel HhMzEb1, belonged to Group 1 (Fig 1) that includes E. bieneusi genotypes with low host specificity that are found not only in humans but also in domestic and wild animals worldwide [10,11,14]. This is the second report of genotype S2 in humans, that had only been previously reported in Malawi from three children (2 HIV-positive and one HIV-negative) and eight HIV-positive adults [35]. Genotype Type IV (also reported previously as K, Peru2, BEB5, CMITS1, BEB-var, PtEB III) has widely been found in humans in different regions throughout the world [5,36-38], with multiple reports in African countries that include Gabon [36], Cameroon [36,39], Uganda [40], Niger [41], Nigeria [31,42,43], Democratic Republic of São Tomé and Principe [30], and Malawi [35] (S5 Table). In addition, Type IV has also been reported in a wide range of animal hosts including non-human primates, cattle, cats, dogs, rodents, birds, snakes, and black bears (S5 Table) as well as in water samples [44-47]. There are no previous reports of Peru11 (also reported previously as Peru12) in humans in Africa, but it has been found in humans in Asia and South America (S5 Table). In Africa, Peru11 has been found in a baboon in Kenya [48]. In addition, there are also reports of this genotype in other parts of the world in non-human primates, cats, raccoons, rabbits, rodents, and birds (S5 Table).

In this study, no mixed infections by different E. bieneusi genotypes were noticed using ITS-PCR and Sanger sequencing. However, it should be noted that co-infections seem a common finding in human populations in endemic areas. Indeed, intra-isolate diversity has been demonstrated in children with diarrhoea in Uganda using microsatellite markers (in addition to ITS) and subsequent cloning and sequencing of PCR products [49]. These data preclude us to conclusively state that mixed infections are not present in the surveyed Mozambican population as the methodology used in this study was not chosen to address mixed infections. The identification of potentially zoonotic genotypes Peru11 and Type IV, commonly found not only in humans but also in domestic and wild animals worldwide, indicates the potential for zoonotic or cross-species transmission. There are few studies in the African continent that include molecular characterization of E. bieneusi in humans and in animals. However, environmental (water) samples should be also considered as a source of infection by microsporidia, as E. bieneusi has been demonstrated to be involved in waterborne outbreaks of gastrointestinal disease [50]. Our findings emphasize the need of further studies to explore risk associations as these were limited in our study by the low prevalence and missing information. Studies could include water as well as animals that may be in contact with human populations in Mozambique to understand the modes of transmission of E. bieneusi, and, by analogy, of other diarrhoea-causing enteric protist species.

Conclusions

This is the first molecular study of E. bieneusi in Mozambique. The parasite was primarily found in asymptomatic children in Maputo (Manhiça district) and Zambézia province. Molecular characterization detected a novel genotype (HhMzEb1) and three known genotypes (Type IV, Peru11 and S2) in diarrheal and healthy Mozambican children. The identification of genotypes previously described in animals suggests potential zoonotic and anthroponotic transmission. There is a lack of information of E. bieneusi in the African continent in humans, animal hosts and environmental samples. Under the One Health perspective, further genotyping studies are needed to better understand the epidemiology of this parasite.

Occurrence of Enterocytozoon bieneusi in humans in Africa.

Average values for symptomatic and asymptomatic individuals are represented according to reported infection rates summarized in Table 1.

(TIF)

Click here for additional data file.

Main socio-demographic features and risk factors of the asymptomatic schoolchildren population (n = 807) investigated in Zambézia province (Mozambique), 2017‒2019.

(DOCX)

Click here for additional data file.

Main socio-demographic features and risk factors of the symptomatic schoolchildren population (n = 290) attended at public health centres in Zambézia province (Mozambique), 2017‒2018.

(DOCX)

Click here for additional data file.

Main socio-demographic features and risk factors of the asymptomatic children population (n = 109) investigated in Maputo province (Mozambique), 2016‒2018.

(DOCX)

Click here for additional data file.

Main socio-demographic features and risk factors of the symptomatic children population (n = 41) investigated in Maputo province (Mozambique), 2016–2018.

(DOCX)

Click here for additional data file.

Summary of all Enterocytozoon bieneusi genotypes reported in Africa including host and geographic range.

Highlighted in bold are African countries.

(DOCX)

Click here for additional data file.

13 Apr 2020

Dear Dr Carmena,

Thank you very much for submitting your manuscript "First identification of genotypes of Enterocytozoon bieneusi (Microsporidia) among symptomatic and asymptomatic children in Mozambique" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Thuy Le

Guest Editor

PLOS Neglected Tropical Diseases

Todd Reynolds

Deputy Editor

PLOS Neglected Tropical Diseases

***********************

Reviewer's Responses to Questions

Key Review Criteria Required for Acceptance?

As you describe the new analyses required for acceptance, please consider the following:

Methods

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer #1: The manuscript by Salimo Muadica et al report on an extensive survey of Enterocytozoon bieneusi infection in children in Mozambique. These studies are difficult to conduct and the authors deserve credit for surveying a relatively large number of children.

Reviewer #2: (No Response)

Reviewer #3: -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? YES

-Is the study design appropriate to address the stated objectives? YES

-Is the population clearly described and appropriate for the hypothesis being tested? YES

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? YES

-Were correct statistical analysis used to support conclusions? YES

-Are there concerns about ethical or regulatory requirements being met? NO

"Comments to the Author":

In the epigraphs “Collection of stool samples in Zambézia province” and “Collection of stool samples in the Manhiça district, Maputo province”, in my opinion is confused the treatment and sample processing (lines 188-190 and lines 229-231, respectively). The authors could clarify or homogenize this step.

- Line 243: “DNA extraction”. Add: “and purification”.

--------------------

Results

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer #1: Perhaps the most important contribution of the study is the apparent absence of association between diarrhea and Eb.

Reviewer #2: (No Response)

Reviewer #3: -Does the analysis presented match the analysis plan? YES

-Are the results clearly and completely presented? YES

-Are the figures (Tables, Images) of sufficient quality for clarity? YES

"Comments to the Author":

- Line 328: “Overall, E. bieneusi was detected by PCR”. Add: nested.

- Table 1: Include in the table foot (legend), TEM (transmission electron microscopy).

- Table 3: Remove in table foot “NA: not applicable”, I think it is not used.

- S3 Table: Remove in table foot “NA: not applicable”, I think it is not used.

--------------------

Conclusions

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer #1: Given the size of the study, the small number of positives is worth reporting, but statements comparing the prevalence in the 2 study sites (line 328, 412) and between this and previously published reports (lines 414-425) may not be warranted unless supported by a statistical analysis. Similarly, the statement on line 333 about the absence of mixed infections seems problematic given the PCR and sequencing method used in this study; see for instance Widmer G, Dilo J, Tumwine JK, Tzipori S, Akiyoshi DE. Appl Environ Microbiol. 2013, Sep;79(17):5357-62.

Reviewer #2: (No Response)

Reviewer #3: -Are the conclusions supported by the data presented? YES

-Are the limitations of analysis clearly described? YES

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? YES

-Is public health relevance addressed? YES

"Comments to the Author": (Discussion).

- Lines 455-461: Comment: The authors should cite or comment the importance of the water transmission of the parasite for a better knowledge of the transmission pathways in the context in which the study was carried out.

--------------------

Editorial and Data Presentation Modifications?

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”.

Reviewer #1: The manuscript is generally well written, but some additional editing seems warranted. See following examples:

Line 206-219. Consider reporting enrollment criteria as a numbered or bulleted list. Text using numerous parentheses and nested parentheses is difficult to follow.

Line 103. …capable of colonizing/infecting a broad spectrum…

Line 110. nearly 500 genotypes

Line 113. …mammalian species, including humans…

Line 126. …could be more frequent that anticipated. Despite the progress…

Line 156. delete “the” (…under reference number…)

Line 186. …seeking medical attention… (no “for” preposition)

Line 192. …children were between 3 and 14 years old.

Line 201. delete “continuous” (it’s implied in the sentence); something is missing after (HDDS), like program or survey?

Line 202. Start new sentence: This survey covers approximately…

Line 208. peripheral health facilities

Line 224. …were enrolled starting in April 2017.

Line 230. testing for enteric pathogens

Line 249. In Manhica, DNA was manually extracted and purified using the QIA….

etc.

Reviewer #2: (No Response)

Reviewer #3: "Comments to the Author":

Keywords:

- Add: novel genotype.

Abstract:

- Line 33: “Enterocytozoon bieneusi (Phylum Microsporidia)”. Comment: With the new classification of the Eukaryotes, in my opinion the Microsporidia (Fungi) is not a Phylum.

Reference: 1: Adl SM, Bass D, Lane CE, Lukeš J, Schoch CL, Smirnov A, Agatha S, Berney C,Brown MW, Burki F, Cárdenas P, Čepička I, Chistyakova L, Del Campo J, Dunthorn M,Edvardsen B, Eglit Y, Guillou L, Hampl V, Heiss AA, Hoppenrath M, James TY, Karnkowska A, Karpov S, Kim E, Kolisko M, Kudryavtsev A, Lahr DJG, Lara E, Le Gall L, Lynn DH, Mann DG, Massana R, Mitchell EAD, Morrow C, Park JS, Pawlowski JW, Powell MJ, Richter DJ, Rueckert S, Shadwick L, Shimano S, Spiegel FW, Torruella G, Youssef N, Zlatogursky V, Zhang Q. Revisions to the Classification, Nomenclature, and Diversity of Eukaryotes. J Eukaryot Microbiol. 2019 Jan;66(1):4-119.

Introduction:

- Line 92: “Microsporidia comprises 200 genera and nearly 1,500 species of spore-forming parasites”. Add: “Microsporidia (Fungi) comprises 200 genera and nearly 1,500 species of spore-forming parasites”.

- Lines 95-96: “causing gastrointestinal infections globally”. Add: “and other disorders and pathologies such as in lung”.

Reference: “del Águila C, Lopez-Velez R, Fenoy S, Turrientes C, Cobo J, Navajas R, Visvesvara GS, Croppo GP, Da Silva AJ, Pieniazek NJ. Identification of Enterocytozoon bieneusi spores in respiratory samples from an AIDS patient with a 2-year history of intestinal microsporidiosis. J Clin Microbiol. 1997, Jul; 35(7): 1862-6”.

- Lines 105-107: “Infections are acquired through ingestion of food or water contaminated with E. bieneusi spores, or through direct contact with faeces of infected persons and animals”. Add: soils.

- Lines 118-120: “GEMS included in their study enteric protozoan parasites Giardia duodenalis, Cryptosporidium spp., and Entamoeba histolytica, but not E. bieneusi”. Comment: E. bieneusi is not a protozoa parasite. Add: enteric parasites, for example.

- Line 130: “asymptomatic paediatric populations”. Change for “pediatric”.

Materials and Methods:

In the epigraphs “Collection of stool samples in Zambézia province” and “Collection of stool samples in the Manhiça district, Maputo province”, in my opinion is confused the treatment and sample processing (lines 188-190 and lines 229-231, respectively). The authors could clarify or homogenize this step.

- Line 243: “DNA extraction”. Add: “and purification”.

Results:

- Line 328: “Overall, E. bieneusi was detected by PCR”. Add: nested.

Discussion:

- Lines 455-461: Comment: The authors should cite or comment the importance of the water transmission of the parasite for a better knowledge of the transmission pathways in the context in which the study was carried out.

Tables:

- Table 1: Include in the table foot (legend), TEM (transmission electron microscopy).

- Table 3: Remove in table foot “NA: not applicable”, I think it is not used.

- S3 Table: Remove in table foot “NA: not applicable”, I think it is not used.

References:

- Add: “Adl SM, Bass D, Lane CE, Lukeš J, Schoch CL, Smirnov A, Agatha S, Berney C,Brown MW, Burki F, Cárdenas P, Čepička I, Chistyakova L, Del Campo J, Dunthorn M,Edvardsen B, Eglit Y, Guillou L, Hampl V, Heiss AA, Hoppenrath M, James TY, Karnkowska A, Karpov S, Kim E, Kolisko M, Kudryavtsev A, Lahr DJG, Lara E, Le Gall L, Lynn DH, Mann DG, Massana R, Mitchell EAD, Morrow C, Park JS, Pawlowski JW, Powell MJ, Richter DJ, Rueckert S, Shadwick L, Shimano S, Spiegel FW, Torruella G, Youssef N, Zlatogursky V, Zhang Q. Revisions to the Classification, Nomenclature, and Diversity of Eukaryotes. J Eukaryot Microbiol. 2019 Jan;66(1):4-119”.

- Add: “del Águila C, Lopez-Velez R, Fenoy S, Turrientes C, Cobo J, Navajas R, Visvesvara GS, Croppo GP, Da Silva AJ, Pieniazek NJ. Identification of Enterocytozoon bieneusi spores in respiratory samples from an AIDS patient with a 2-year history of intestinal microsporidiosis. J Clin Microbiol. 1997, Jul; 35(7): 1862-6”.

--------------------

Summary and General Comments

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer #1: The apparent absence of association between diarrhea and Eb is worth reporting. Some of the conclusions should be supported by statistical tests.

Reviewer #2: (No Response)

Reviewer #3: The main objective of the manuscript is very interesting with promising results. In my opinion would have been interesting to investigate the presence of other species of Microsporidia (for example Encephalitozoon spp) using others complementary techniques such as staining methods or immunological techniques.

Obviously, the authors want to study only the genotypes of E. bieneusi in children in Africa (Mozambique) as main objective. But these additional techniques (staining methods or immunological techniques) could contribute to knowledge of the prevalence of other species of Microsporidia and provide us of a valuable information for this study or for new studies in the future.

I enjoyed reviewing this article. It is extensive with detailed information with a complete review of the prevalence of E. bieneusi and its genotypes in Africa. The results are interesting highlighting the description of a novel genotype. I encourage the authors to continue investigating the circulation and prevalence of this novel genotype and those already described in Africa.

--------------------

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Giovanni Widmer

Reviewer #2: No

Reviewer #3: Yes: Dr. Fernando Izquierdo Arias.

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see https://journals.plos.org/plosntds/s/submission-guidelines#loc-methods

Submitted filename: RewierComments_PNTD-D-20-00113.docx

Click here for additional data file.

12 May 2020

Submitted filename: Letter to reviewers PNTD-D-20-00113.docx

Click here for additional data file.

23 May 2020

Dear Dr Carmena,

We are pleased to inform you that your manuscript 'First identification of genotypes of Enterocytozoon bieneusi (Microsporidia) among symptomatic and asymptomatic children in Mozambique' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Thuy Le

Guest Editor

PLOS Neglected Tropical Diseases

Todd Reynolds

Deputy Editor

PLOS Neglected Tropical Diseases

***********************************************************

18 Jun 2020

Dear Dr Carmena,

We are delighted to inform you that your manuscript, "First identification of genotypes of Enterocytozoon bieneusi (Microsporidia) among symptomatic and asymptomatic children in Mozambique," has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases